What Makes Trevi Therapeutics a New Buy Stock

TRVI Stock  USD 4.03  0.04  0.98%   
Under 68% of Trevi Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Trevi Therapeutics stock suggests that many investors are alarmed at this time. Trevi Therapeutics' investing sentiment shows overall attitude of investors towards Trevi Therapeutics.
  
Trevi Therapeutics might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 .

Read at zacks.com
zacks News
  

Trevi Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Trevi Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Trevi Therapeutics Fundamental Analysis

We analyze Trevi Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trevi Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trevi Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Trevi Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Trevi Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Trevi Therapeutics stock to make a market-neutral strategy. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics with similar companies.

Peers

Trevi Therapeutics Related Equities

CCCCC4 Therapeutics   0.52   
5.0%
ANEBAnebulo Pharmaceuticals   0.61   
6.0%
FHTXFoghorn Therapeutics   0.85   
9.0%
TARAProtara Therapeutics   1.17   
12.0%
SEERSeer   1.63   
17.0%
BOLTBolt Biotherapeutics   1.72   
18.0%
ANTXAN2 Therapeutics   3.70   
39.0%
CGEMCullinan Oncology   3.72   
39.0%
CHRSCoherus BioSciences   3.82   
40.0%
RZLTRezolute   4.05   
43.0%
SPROSpero Therapeutics   4.76   
50.0%
PRLDPrelude Therapeutics   5.79   
61.0%
BCABBioatla   6.67   
71.0%
ORICOric Pharmaceuticals   7.81   
83.0%
LYRALyra Therapeutics   9.09   
96.0%
CUECue Biopharma   9.38   
100.0%

Complementary Tools for Trevi Stock analysis

When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Stocks Directory
Find actively traded stocks across global markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk